Related coverage linked through entity extraction aliases.
Jul 29, 2026
ChrysCapital-led open offer for Novartis India saw only 40 shares accepted. The consortium acquired Novartis AG's 70.68% stake for Rs 1,445.8 crore; public shareholding now stands at 29.32%.
Mar 23, 2026
Bio-Thera Solutions expands its partnership with Intas Pharmaceuticals for BAT2506, a golimumab biosimilar, through an exclusive commercialization agreement for India. The India biosimilars market is projected to grow from $184 million to $1.02 billion by 2035, driven by patent expirations and strategic partnerships.
Feb 20, 2026
Swiss pharmaceutical major Novartis AG has signed a definitive agreement to sell its entire 70.68% stake in Novartis India to a ChrysCapital-led consortium for Rs 1,446 crore, with a mandatory open offer for an additional 26% from public shareholders.
